Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 5 | 3 |
| List of Figures | 8 | 2 |
| Bone and Joint Infecmtion Market to 2016: Introduction | 10 | 1 |
| GBI Research Report Guidance | 10 | 1 |
| Bone and Joint Infection Market to 2016: Market Overview | 11 | 9 |
| Introduction | 11 | 1 |
| Revenue Forecasts for the Global Bone and Joint Infection Market | 11 | 1 |
| Revenue | 11 | 2 |
| Annual Cost of Treatment (ACT) | 13 | 1 |
| Treatment Usage Patterns | 14 | 2 |
| Diseased Population | 16 | 1 |
| Treatment Seeking Population | 17 | 1 |
| Diagnosis Population | 18 | 1 |
| Prescription Population | 19 | 1 |
| Bone and Joint Infection Market to 2016: Geographical Landscape | 20 | 25 |
| Revenue Analysis by Geography | 20 | 2 |
| The US | 22 | 1 |
| Revenue | 22 | 1 |
| Annual Cost of Treatment (ACT) | 23 | 1 |
| Treatment Usage Patterns | 24 | 1 |
| Diseased Population | 25 | 1 |
| Treatment Seeking Population | 26 | 1 |
| Diagnosed Population | 27 | 1 |
| Prescription Population | 28 | 1 |
| Top Five Countries in Europe | 29 | 1 |
| Revenue | 29 | 1 |
| Annual Cost of Treatment (ACT) | 30 | 1 |
| Treatment Usage Patterns | 31 | 2 |
| Diseased Population | 33 | 1 |
| Treatment Seeking Population | 34 | 1 |
| Diagnosed Population | 35 | 1 |
| Prescription Population | 36 | 1 |
| Japan | 37 | 1 |
| Revenue | 37 | 1 |
| Annual Cost of Treatment (ACT) | 38 | 1 |
| Treatment Usage Patterns | 39 | 2 |
| Diseased Population | 41 | 1 |
| Treatment Seeking Population | 42 | 1 |
| Diagnosed Population | 43 | 1 |
| Prescription Population | 44 | 1 |
| Bone and Joint Infection Market to 2016: Therapeutic Landscape | 45 | 31 |
| Prosthetic Joint Infections Therapeutics Market | 45 | 1 |
| Introduction | 45 | 1 |
| Revenue | 46 | 1 |
| Annual Cost of Treatment | 47 | 1 |
| Treatment Usage Patterns | 48 | 2 |
| Diseased Population | 50 | 1 |
| Treatment Seeking Population | 51 | 1 |
| Diagnosed Population | 52 | 1 |
| Prescription Population | 53 | 1 |
| Drivers and Barriers for the Prosthetic Joint Infections Therapeutics Market | 54 | 1 |
| Drivers for the Prosthetic Joint Infections Therapeutics Market | 54 | 1 |
| Increasing Use of High Cost Antibiotics | 54 | 1 |
| Increase in Joint Replacement Therapies for Arthritis and Joint Infections | 54 | 1 |
| Increasing treatment seeking population | 54 | 1 |
| Barriers for the Prosthetic Joint Infections Therapeutics Market | 55 | 1 |
| Availability of Alternative Options | 55 | 1 |
| Opportunity and Unmet Need | 55 | 1 |
| Osteomyelitis Therapeutics Market | 55 | 1 |
| Introduction | 55 | 1 |
| Revenue | 56 | 1 |
| Annual Cost of Treatment (ACT) | 57 | 1 |
| Treatment Usage Patterns | 58 | 2 |
| Diseased Population | 60 | 1 |
| Treatment Seeking Population | 61 | 1 |
| Diagnosed Population | 62 | 1 |
| Prescription Population | 63 | 1 |
| Drivers and Barriers for the Osteomyelitis Therapeutics Market | 64 | 1 |
| Drivers for the Osteomyelitis Therapeutics Market | 64 | 1 |
| Introduction of novel drug therapies | 64 | 1 |
| Diagnosis Rate | 64 | 1 |
| Barriers for the Osteomyelitis Therapeutics Market | 65 | 1 |
| Lower Patient Affordability | 65 | 1 |
| Low Treatment Seeking Rate | 65 | 1 |
| Opportunity and Unmet Need | 65 | 1 |
| Septic Arthritis Therapeutics Market | 65 | 1 |
| Introduction | 65 | 1 |
| Revenue | 66 | 1 |
| Annual Cost of Treatment (ACT) | 67 | 1 |
| Treatment Usage Patterns | 68 | 2 |
| Diseased Population | 70 | 1 |
| Treatment Seeking Population | 71 | 1 |
| Diagnosed Population | 72 | 1 |
| Prescription Population | 73 | 1 |
| Drivers and Barriers for the Septic Arthritis Therapeutics Market | 74 | 1 |
| Drivers for the Septic Arthritis Therapeutics Market | 74 | 1 |
| Availability of alternative options | 74 | 1 |
| Increasing treatment seeking rate | 74 | 1 |
| Barriers for the Septic Arthritis Therapeutics market | 75 | 1 |
| Improper diagnosis of septic arthritis | 75 | 1 |
| Opportunity and Unmet Need | 75 | 1 |
| Bone and Joint Infection Market to 2016: Pipeline Analysis | 76 | 13 |
| Introduction | 76 | 1 |
| Research and Development Pipeline-Bone and Joint Infection | 76 | 5 |
| Profiles of Key Late Stage Drugs in the Bone and Joint Infection Market | 81 | 1 |
| Pagibaximab | 81 | 1 |
| Overview | 81 | 1 |
| Efficacy | 81 | 1 |
| Safety | 81 | 1 |
| Clinical Study Details | 81 | 1 |
| TAKSTA | 81 | 1 |
| Overview | 81 | 1 |
| Efficacy | 81 | 1 |
| Safety | 81 | 1 |
| Clinical Study Details | 81 | 1 |
| V710 | 82 | 1 |
| Overview | 82 | 1 |
| Efficacy | 82 | 1 |
| Safety Profile | 82 | 1 |
| Clinical Study Details | 82 | 1 |
| Ceftobiprole | 82 | 1 |
| Overview | 82 | 1 |
| Efficacy | 83 | 1 |
| Safety Profile | 83 | 1 |
| Clinical Study Details | 83 | 1 |
| Teflaro | 84 | 1 |
| Overview | 84 | 1 |
| Efficacy | 84 | 1 |
| Safety Profile | 85 | 1 |
| Clinical Study Details | 85 | 1 |
| Torezolid | 86 | 1 |
| Overview | 86 | 1 |
| Efficacy | 86 | 1 |
| Safety Profile | 86 | 1 |
| Clinical Study Details | 87 | 1 |
| Rotarix + Infanrix + Pediarix + GSK 208108 + Prevnar 13 | 87 | 1 |
| Overview | 87 | 1 |
| Safety Profile and Efficacy | 88 | 1 |
| Clinical Study Details | 88 | 1 |
| Bone and Joint Infection Market to 2016: Competitive Landscape | 89 | 22 |
| Overview | 89 | 1 |
| Competitive Profiling | 89 | 1 |
| Sandoz GmbH | 89 | 1 |
| Company Overview | 89 | 1 |
| Marketed Products | 89 | 2 |
| GlaxoSmithKline | 91 | 1 |
| Company Overview | 91 | 1 |
| Marketed Products | 92 | 1 |
| F. Hoffmann-La Roche Ltd. | 93 | 1 |
| Company Overview | 93 | 1 |
| Marketed Products | 94 | 1 |
| Ranbaxy | 94 | 1 |
| Company Overview | 94 | 1 |
| Marketed Products | 95 | 1 |
| Bayer AG | 96 | 1 |
| Company Overview | 96 | 1 |
| Marketed Products | 97 | 2 |
| Teva Pharmaceutical Industries Limited | 99 | 1 |
| Company Overview | 99 | 1 |
| Marketed Products | 99 | 3 |
| Eli Lilly and Company | 102 | 1 |
| Company Overview | 102 | 1 |
| Marketed Products | 102 | 2 |
| Pfizer Inc. | 104 | 1 |
| Company Overview | 104 | 1 |
| Marketed Products | 104 | 2 |
| Hospira, Inc. | 106 | 1 |
| Company Overview | 106 | 1 |
| Marketed Products | 106 | 1 |
| LEO Pharma A/S | 107 | 1 |
| Company Overview | 107 | 1 |
| Marketed Products | 108 | 1 |
| APP Pharmaceuticals, Inc. | 108 | 1 |
| Company Overview | 108 | 1 |
| Marketed Products | 109 | 1 |
| Abbott Laboratories | 109 | 1 |
| Company Overview | 109 | 1 |
| Marketed Products | 109 | 2 |
| Bone and Joint Infection Market to 2016: M&A Landscape | 111 | 5 |
| Global Bone and Joint Infection Market | 111 | 1 |
| Overview: Deals by Type | 111 | 1 |
| Mergers and Acquisitions | 112 | 1 |
| Overview | 112 | 1 |
| Durata Therapeutics Acquires Vicuron Pharmaceuticals | 112 | 1 |
| Aptuit Acquires Medicines Research Centre from GlaxoSmithKline | 112 | 1 |
| Hospira Acquires Pliva | 113 | 1 |
| Licensing Agreements | 114 | 1 |
| GlaxoSmithKline (GSK) and Isis Pharmaceuticals | 114 | 1 |
| Sanofi-aventis and Novozymes | 114 | 1 |
| Deals by Geography | 114 | 1 |
| Deals by Year | 115 | 1 |
| Bone and Joint Infection Market to 2016: Appendix | 116 | 6 |
| Market Definition | 116 | 1 |
| Abbreviations | 116 | 1 |
| Research Methodology | 117 | 4 |
| Coverage | 117 | 1 |
| Secondary Research | 117 | 1 |
| Forecasting | 118 | 1 |
| Epidemiology-based Forecasting | 118 | 2 |
| Primary Research | 120 | 1 |
| Expert Panels | 120 | 1 |
| Contact Us | 120 | 1 |
| Disclaimer | 121 | 1 |
| Sources | 121 | 1 |